Skip to content

Clinical trials

Observational Mucopolysaccharidosis IV trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Mucopolysaccharidosis IV Phase: Observational Country / region: United States Clear all

25 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20081
20091
20111
20124
20132
20142
20171
20181
20191
20201
20212
20222
20231
20241
20252

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed12
Recruiting7
Terminated3
Active, not recruiting1
Enrolling by invitation1
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
BioMarin Pharmaceutical2
Emory University2
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2
Nadia Ali, PhD2
QED Therapeutics, a BridgeBio company2
Albert Einstein College of Medicine1
Augusta University1
Children's Hospital of Orange County1
Children's Hospitals and Clinics of Minnesota1
Greenwood Genetic Center1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Mucopolysaccharidosis IV25
Mucopolysaccharidosis VI7
Dwarfism5
Mucopolysaccharidoses5
Mucopolysaccharidosis II5
Mucopolysaccharidosis I4
Mucopolysaccharidosis VII4
Gaucher Disease3
Genetic Diseases, Inborn3
Lysosomal Storage Diseases3

Trials

Showing 1 to 25 of 25. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.